LifeTech Capital Maintains Bionovo Strong Speculative Buy, Lowers PT

20-Year Pro Trader Reveals His "MoneyLine"

Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.

LifeTech Capital maintained its Bionovo (NASDAQ: BNVI) Strong Speculative Buy rating and lowered its Bionovo price target from $7.50 to $5 in a research report published today.In the report, LifeTech Capital states, "Menerba could become the first botanical blockbuster drug which we believe represents an intriguing opportunity for patient investors."Shares of Bionovo were trading at $0.69 at the time of posting, down 12.41% from Tuesday's market close.

20-Year Pro Trader Reveals His "MoneyLine"

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!